ALPINE IMMUNE SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

ALPINE IMMUNE SCIENCES, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum

ALPINE IMMUNE SCIENCES, INC. reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum of 85.00% for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-20.

Discontinued › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum · last filed 2024-03-20

• ALPINE IMMUNE SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2023 was 85.00%, a 2.41% increase from fiscal 2022.
• ALPINE IMMUNE SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2022 was 83.00%, a 0.00% change from fiscal 2021.
• ALPINE IMMUNE SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2021 was 83.00%, a 1.22% increase from fiscal 2020.
• ALPINE IMMUNE SCIENCES, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate, maximum for fiscal 2020 was 82.00%, a 6.49% increase from fiscal 2019.